Beranda › Glioblastoma › California › Sacramento
Uji klinis Glioblastoma di Sacramento, CA
4 studi untuk Glioblastoma mencari peserta di lokasi sekitar Sacramento (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
Menerima pesertaFase 1/2
- University of California Davis Comprehensive Cancer Center, Sacramento
Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma
Menerima pesertaFase 1
- University of California Davis Comprehensive Cancer Center, Sacramento
Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma
Menerima pesertaFase 3
- University of California Davis Comprehensive Cancer Center, Sacramento
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
Menerima pesertaFase 1
- University of California Davis Comprehensive Cancer Center, Sacramento
Uji klinis Glioblastoma di kota lain
- New York City, NY30 studi
- Boston, MA28 studi
- Houston, TX26 studi
- Los Angeles, CA24 studi
- Durham, NC20 studi
- San Francisco, CA17 studi
- Chicago, IL15 studi
- Washington, DC15 studi
- Columbus, OH14 studi
- Miami, FL14 studi
- Rochester, MN13 studi
- Jacksonville, FL13 studi
Studi lain di Sacramento
- Kanker Paru Non-Sel Kecil29 studi
- Kanker Paru22 studi
- Kanker Payudara20 studi
- Kanker Prostat19 studi
- Kanker Metastatik16 studi
- Leukemia Mieloid Akut12 studi
- Gagal Jantung12 studi
- Kanker Pankreas12 studi
- Kanker (semua jenis)11 studi
- Kanker Kolon11 studi
- Kanker Kandung Kemih10 studi
- Kanker Kolorektal10 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.